<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006347</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068199</org_study_id>
    <secondary_id>CMMI-C-057A-99</secondary_id>
    <secondary_id>NCI-H00-0064</secondary_id>
    <nct_id>NCT00006347</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer</brief_title>
  <official_title>Phase I Non-Myeloablative Trial With 90Y-Humanized MN-14 (Anti-CEA) Antibody for Relapsed or Refractory Small Cell Lung Cancer (SCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Garden State Cancer Center at the Center for Molecular Medicine and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating&#xD;
      patients who have relapsed or refractory small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the dose limiting toxicity and maximum tolerated dose of yttrium Y 90 anti-CEA&#xD;
           monoclonal antibody MN-14 in patients with relapsed or refractory small cell lung&#xD;
           cancer.&#xD;
&#xD;
        -  Determine the dosimetric and pharmacokinetic properties of this treatment regimen in the&#xD;
           blood, normal organs, and tumors of these patients.&#xD;
&#xD;
        -  Determine the stability and complexation with circulating carcinoembryonic antigen of&#xD;
           this radioantibody in the plasma of these patients.&#xD;
&#xD;
        -  Determine the antibody response of these patients treated with this regimen.&#xD;
&#xD;
        -  Determine the antitumor effects of this treatment regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of yttrium Y 90 anti-CEA monoclonal antibody MN-14&#xD;
      (90Y-hMN-14). Patients are stratified according to prior radiotherapy (yes vs no).&#xD;
&#xD;
      Patients undergo pretherapy imaging with indium In 111 anti-CEA monoclonal antibody MN-14 IV&#xD;
      over 30-40 minutes on day -7 or -6 followed by external scintigraphy on days -7 or -6 to 0.&#xD;
&#xD;
      Patients who show positive localization of at least one documented tumor site receive&#xD;
      90Y-hMN-14 IV over 30-40 minutes on day 0.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of 90Y-hMN-14 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 3 or 2 of 6 patients experience dose limiting toxicity.&#xD;
&#xD;
      Patients are followed at 2, 4, 8, and 12 weeks; every 3 months for 2 years; and then every 6&#xD;
      months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 10-14&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2000</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium In 111 monoclonal antibody MN-14</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 monoclonal antibody MN-14</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed small cell lung cancer (SCLC)&#xD;
&#xD;
               -  Must have received at least one prior course of standard chemotherapy and, if&#xD;
                  indicated, up to 6,900 cGy of thoracic radiotherapy&#xD;
&#xD;
               -  Patients who received prior radiotherapy must show evidence of progressive&#xD;
                  disease&#xD;
&#xD;
               -  Patients who received no prior radiotherapy to the primary tumor must show&#xD;
                  evidence of stable or progressive disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Must have evidence of carcinoembryonic antigen (CEA) production or expression&#xD;
             documented by one of the following:&#xD;
&#xD;
               -  Serum CEA at least 10 ng/mL&#xD;
&#xD;
               -  Positive immunohistology of either the primary tumor or a metastasis with CEA&#xD;
                  specific monoclonal antibody&#xD;
&#xD;
          -  Must have unilateral bone marrow biopsy with less than 25% tumor involvement&#xD;
&#xD;
          -  No known, active brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL&#xD;
&#xD;
          -  AST no greater than 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  No hepatitis B or C&#xD;
&#xD;
          -  No other serious liver abnormality&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No urinary incontinence&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction at least 50%&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV_1 and FVC at least 60%&#xD;
&#xD;
          -  DLCO at least 50% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No severe anorexia, nausea, or vomiting&#xD;
&#xD;
          -  No other significant medical problems&#xD;
&#xD;
          -  No prisoners&#xD;
&#xD;
          -  No reactivity to humanized MN-14 (in patients with prior exposure to chimeric or&#xD;
             humanized antibody)&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active HIV-related disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 3 months&#xD;
             following study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  No concurrent growth factors (e.g., filgrastim [G-CSF])&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior high dose chemotherapy with stem cell transplantation&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  Prior radiotherapy to less than 30% of red marrow (including standard chest x-ray for&#xD;
             limited stage SCLC) allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack D. Burton, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Garden State Cancer Center at the Center for Molecular Medicine and Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Garden State Cancer Center</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>October 4, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 28, 2009</last_update_submitted>
  <last_update_submitted_qc>February 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2009</last_update_posted>
  <keyword>recurrent small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

